Phreesia, Inc. (PHR) Stock Price & Analysis
Phreesia, Inc. (PHR) fell 0.54% to USD 9.29 as of June 10, 2026 at 05:03 UTC, according to Nexqual real-time market data.
PHR last closed at USD 9.34; the session ranged USD 9.12–9.64 on volume of 651,266 shares. Market capitalization is $574.23M, with a 52-week range of USD 7.77–32.76 (NYQ). Source: Nexqual, June 10, 2026 at 05:03 UTC.
Key Statistics (as of June 10, 2026 at 05:03 UTC)
| Price | USD 9.29 |
|---|---|
| Change | ▼ 0.54% (down) |
| Previous Close | USD 9.34 |
| Open | USD 9.22 |
| Day Range | USD 9.12 – 9.64 |
| 52-Week Range | USD 7.77 – 32.76 |
| Volume | 651,266 shares |
| Market Cap | $574.23M |
| Exchange | NYQ |
Technical Analysis (PHR)
Nexqual's technical model rates PHR "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 05:03 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.51 (neutral) |
| vs SMA50 | Below (USD 9.3) |
| MACD | 0.06 (positive) |
Analyst Ratings (PHR)
Wall Street analysts rate PHR "Buy" based on 18 analysts, with a mean price target of USD 14.28 (range USD 9–20), per Nexqual as of June 10, 2026 at 05:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 14.28 |
| High Target | USD 20 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 12 / 8 / 0 |
Earnings (PHR)
| Next Earnings Date | 2026-05-27 |
|---|---|
| EPS Estimate | USD 0.32 |
| Revenue Estimate | $129.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-04-30 | USD 0.19 vs est 0.29 ▼ miss |
| 2026-01-31 | USD 0.44 vs est 0.32 ▲ beat |
| 2025-10-31 | USD 0.31 vs est 0.24 ▲ beat |
| 2025-07-31 | USD 0.27 vs est 0.19 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Financials & Fundamentals (PHR)
| Total Revenue | $495.59M |
|---|---|
| Revenue Growth (YoY) | +12.90% |
| Gross Margin | +67.84% |
| Operating Margin | +5.15% |
| Profit Margin | +1.85% |
| ROE | +2.86% |
| Debt / Equity | 25.78 |
| Current Ratio | 1.76 |
| Total Cash | $74.71M |
| Total Debt | $92.56M |
| Free Cash Flow | $56.36M |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Financial Health Score (PHR)
Nexqual rates Phreesia, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 05:03 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 5% |
| Balance Sheet | Strong — $75M cash vs $93M debt |
| Cash Flow | Solid — FCF $56M, 12% margin |
| Efficiency | Weak — ROE 3%, ROA 1.5% |
Ownership (PHR)
| Insider Ownership | +4.26% |
|---|---|
| Institutional Ownership | +97.62% |
| Shares Outstanding | 61.81M |
| Float | 49.98M |
| Short % of Float | +6.69% |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Leadership (PHR)
Phreesia, Inc. is led by Chaim Indig (age 45), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 05:03 UTC.
| Co-Founder, CEO & Director | Chaim Indig (age 45) |
|---|---|
| Co-Founder & President of Provider Solutions | Evan Roberts (age 45) |
| Chief Financial Officer | Balaji Gandhi (age 50) |
| President of Network Solutions | David Linetsky (age 44) |
| Chief Technology Officer | Jack Callahan |
Major Backers & Investors (PHR)
Notable institutional backers of Phreesia, Inc. include Pale Fire Capital SE, AQR Capital Management, LLC, Algert Global, LLC, according to Nexqual as of June 10, 2026 at 05:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pale Fire Capital SE | 13.99% |
| AQR Capital Management, LLC | 3% |
| Algert Global, LLC | 2.23% |
| Franklin Strategic Series-FRANKLIN SMALL CAP GROWTH FUND | 2.23% |
| Prosight Management, Lp | 1.78% |
| Jacobs Levy Equity Management, Inc. | 1.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.47% |
| BlackRock | 11.79% |
| State Street | 2.38% |
| Geode Capital | 2.22% |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
From Phreesia, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Platform and Solutions Phreesia's integrated platform is designed to address challenges patients and healthcare providers face in three core areas: Access, Affordability, and Outcomes.
- We have industry certifications, including HITRUST, PCI-DSS Level 1 Service Provider, Systems and Organization Controls 2 ("SOC 2") and PCI Point-to-Point Encryption.
- Accordingly, new competitors or providers of EHR and PM solutions may emerge that have greater market share, larger client bases, more widely adopted proprietary technologies, greater marketing expertise, new or better AI technologies, greater financial resources and larger sales forces than we have, which could put us at a competitive disadvantage and could render our existing or future products less competitive or obsolete.
- In fiscal year 2026, our platform facilitated approximately 180 million patient visits, representing approximately one in six ambulatory patient visits in the United States.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCAT | Health Catalyst, Inc | USD 1.71 | ▼ 11.4% |
| VCYT | Veracyte, Inc. | USD 49.24 | ▲ 1.05% |
| CSTL | Castle Biosciences, Inc. | USD 21.08 | ▲ 0.33% |
| LOB | Live Oak Bancshares, Inc. | USD 38.63 | ▲ 3.26% |
| HQY | HealthEquity, Inc. | USD 89.23 | ▲ 0.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:03 UTC. This page is informational and not investment advice.